ArticlePulmonary circulation2026
Prevalence, Characteristics, and Outcomes Associated With Early Vasculopathy in Patients With Chronic Lung Disease Undergoing Right Heart Catheterization.
Article in Pulmonary circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary hypertension associated with chronic lung disease (PH-CLD) meets precapillary PH criteria. Less is known CLD patients with "early vasculopathy," a phenotype characterized by elevated pulmonary vascular resistance (PVR) and normal mean pulmonary artery pressure (mPAP). In this study, we aimed to determine the prevalence, characteristics, and outcomes of the early vasculopathy phenotype among CLD patients. We performed a retrospective cohort analysis of adults with chronic obstructive pulmonary disease or obstructive sleep apnea undergoing right heart catheterization between 2018 and 2023. Patients were categorized into three cohorts: non-PH cohort (mPAP ≤ 20 mmHg, PVR ≤ 2 WU), early vasculopathy cohort (mPAP ≤ 20 mmHg, PVR > 2 WU), and precapillary PH cohort (mPAP > 20 mmHg, PVR > 2 WU). The primary endpoint was a 1-year composite of mortality and major adverse cardiovascular events. Of 243 patients with CLD, 7.4% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.